ReviewAntibiotics (Basel, Switzerland)2025
Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options.
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Divergent roles of OmpA family proteins in physiology, stress tolerance, and virulence ofVirulence · 2026Article
- Beyond the Usual Suspects: EmergingInternational journal of molecular sciences · 2026Review
- First reported Pseudomonas soli bloodstream infection confirmed by whole-genome sequencing after MALDI-TOF misidentification.BMC microbiology · 2026Article
- Managing Pneumonia Due to Rare Non-Fermenting Gram-Negative Bacteria: Epidemiology, Risk Factors and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- Between the Sponge and the Tap-Bacterial Communities at Overlooked Hospital Hygiene Hotspots.Microorganisms · 2026Article
- Influence of substitution patterns on the antimicrobial properties of pyrrole sulfonamide scaffolds.Frontiers in chemistry · 2026Article
- Invasomes and Nanostructured Lipid Carriers for Targeted Delivery of Ceftazidime Combined with N-Acetylcysteine: A Novel Approach to TreatPharmaceutics · 2025Article
- Genomic Insights into Emerging Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Antibiotic Therapy Duration for Multidrug-Resistant Gram-Negative Bacterial Infections: An Evidence-Based Review.International journal of molecular sciences · 2025Review
- Article
- Description of Two Resistance-Nodulation-Cell Division Efflux Systems Involved in Acquired Antibiotic Resistance: AxySUV inAntibiotics (Basel, Switzerland) · 2025Article
- Therapeutic challenges in managingFrontiers in cellular and infection microbiology · 2025Review
- Managing Multidrug-ResistantLe infezioni in medicina · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-fermenting Gram-negative bacteria (NFGNB) are a heterogeneous group of opportunistic pathogens increasingly associated with healthcare-associated infections. While
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.